# Treatment of Congenital Factor VII Deficiency

> **NCT01779921** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 163 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Congenital FVII Deficiency

## Interventions

- **DRUG:** activated recombinant human factor VII
- **DRUG:** Fresh frozen plasma (Source unspecified)
- **DRUG:** Plasma-derived FVII (LFB)
- **DRUG:** Prothrombin Complex conc. (PCC)
- **DRUG:** Plasma-derived FVII conc. (pdFVII Baxter)
- **DRUG:** Plasma-derived FVII conc. (pdFVII PFL)

## Key facts

- **NCT ID:** NCT01779921
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 163 (ACTUAL)
- **Last updated:** 2017-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01779921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01779921, "Treatment of Congenital Factor VII Deficiency". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01779921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*